The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|July 2, 2019
- Pharmaceutical Technology-07-02-2019
- Volume 43
- Issue 7
Planetary Dual Dispersers and Advanced Discharge Systems
The Planetary Dual Disperser is the newest addition to the Ross planetary mixing line of industrial mixers.
The Planetary Dual Disperser (PDDM) is the newest addition to the Ross planetary mixing line of industrial mixers. The system offers a robust combination of kneading and high shear input and delivers efficient processing power for new generation batteries, adhesives, composites, pharmaceuticals, coatings, and chemicals.
Available in sizes upwards of 1000 gallons, the PDDM system includes a planetary dual disperser complete with an advanced dual-post discharge system suited for 100-psig discharge pressure. In the two systems pictured, the semi-continuous mixing and discharge operation uses 10 interchangeable vessels. Each PDDM is equipped with two rectangular stirrers and two dual-blade, high-speed dispersers that rotate on their own axis while orbiting the mixing zone on a common axis. Operator controls feature a 20-step, 20-recipe program ensuring batch-to-batch consistency and complete traceability.
Articles in this issue
over 7 years ago
Playbooks Are Not Just Child’s Playover 7 years ago
New Line of Rotary Valvesover 7 years ago
Updated Pump Headover 7 years ago
FDA Revamps Biosimilar Quality Requirementsover 7 years ago
Plate Reader Offers Real-Time Detection and Analysisover 7 years ago
Automating Quality Checksover 7 years ago
Considerations for Sterile Filtration of Biologic Drugsover 7 years ago
Gene Therapies Propel Outsourcing Investmentover 7 years ago
A Biologics Partisan DivideRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.